Live attenuated influenza vaccine effectiveness against hospitalisation due to laboratory-confirmed influenza in children two to six years of age in England in the 2015/16 season

Euro Surveill. 2017 Jan 26;22(4):30450. doi: 10.2807/1560-7917.ES.2017.22.4.30450.

Abstract

The United Kingdom is introducing a universal annual influenza vaccination programme for children. Live attenuated influenza vaccine (LAIV) effectiveness (VE) against laboratory-confirmed influenza hospitalisation in 2 to 6 year-olds in England was measured in 2015/16 using the screening method. VE adjusted for age, geography and month was 54.5% (95% confidence interval (CI): 31.5% to 68.4%) for all influenza types combined; 48.3% (95% CI: 16.9% to 67.8%) for A(H1N1)pdm09 and 70.6% (95% CI: 33.2% to 87.1%) for B. The findings support on-going programme roll-out.

Keywords: LAIV; hospitalisation; influenza; vaccine effectiveness.

MeSH terms

  • Adolescent
  • Case-Control Studies
  • Child
  • Child, Preschool
  • Disease Outbreaks / prevention & control*
  • England / epidemiology
  • Female
  • Hospitalization / statistics & numerical data*
  • Humans
  • Immunization Programs
  • Influenza A Virus, H1N1 Subtype / immunology
  • Influenza A Virus, H1N1 Subtype / isolation & purification*
  • Influenza B virus / immunology
  • Influenza B virus / isolation & purification
  • Influenza Vaccines / administration & dosage
  • Influenza Vaccines / immunology*
  • Influenza, Human / epidemiology*
  • Influenza, Human / immunology
  • Influenza, Human / prevention & control*
  • Laboratories
  • Male
  • Outcome Assessment, Health Care
  • Seasons
  • Vaccination / statistics & numerical data
  • Vaccine Potency
  • Vaccines, Attenuated / administration & dosage
  • Vaccines, Attenuated / immunology*

Substances

  • Influenza Vaccines
  • Vaccines, Attenuated